Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall procritProcrit has been associated with a number of life-threatening side effects, including:
· The rapid growth of some head and neck tumors
· The rapid growth of metastatic breast cancer
· Adverse cardiovascular events, including heart attack
· The formation of blood clots, particularly in patients with kidney failure and patients undergoing orthopedic surgery
· An increased risk of stroke
Procrit has also been linked to an increased risk of death among cancer patients who are not undergoing chemotherapy.
All ESAs Work the Same Way
Erythropoiesis stimulating agents (ESAs) such as Procrit, Aranesp, and Epogen are prescribed to nearly one million patients in the United States each year. A number of recent studies have found that ESA treatment is associated with potentially fatal side effects for patients with:
· Anemia caused by cancer rather than by chemotherapy
· Head and neck cancer
· Lung cancer
· Blood transfusions given prior to major surgery
If you have been treated with an ESA such as Procrit and suffered a severe Procrit side effect, you may be entitled to compensation for your losses. Contact us to arrange a FREE consultation with an experienced attorney near you.
Procrit Side Effects and Dialysis Risks
In late 2006, The New England Journal of Medicine reported the results of a large clinical study evaluating Procrit’s benefits and risks in patients with chronic kidney disease who were not on dialysis. At the time, the product labeling for Procrit recommended raising a patient’s blood hemoglobin level to no higher than 12 g/dL with Procrit treatment. The study subjects who were treated with Procrit to raise their blood hemoglobin level to 13.5 g/dL experienced greater rates of death and life-threatening Procrit side effects compared to those who were treated to raise their blood hemoglobin level to 11.3 g/dL.
In practice, almost all kidney dialysis patients in the U.S. are treated with an ESA such as Procrit, and almost none of them have hemoglobin levels below 11 g/dL after treatment. In fact, the U.S. Renal Data System reported that about 50% of dialysis patients have levels of more than 12 g/dL and close to 20% have levels above 13 g/dL after ESA treatment.
According to a New York Times investigative report, some scientists believe that kidney dialysis patients, most of whom are on Medicare, are being over-medicated with ESAs because dialysis clinics reap larger profits for providing higher doses of ESAs.
Have You Suffered a Procrit Side Effect?
If you have suffered a serious Procrit side effect, you need to ensure your rights are protected. You may be eligible to recover damages including medical bills, pain and suffering, loss of enjoyment of life, and more. Contact us today to discuss your legal options with a qualified attorney near you.
A Food and Drug Administration advisory panel is recommending restrictions on the use of anemia drugs for cancer patients.
The panel recommendation comes in response to growing safety concerns over the risks associated with the anemia drugs Ar...
Anemia drugs known as erythropoiesis-stimulating agents (ESAs) may speed up cancer growth and lead to earlier death in some patients, the Food and Drug Administration announced today citing two new studies.
November Warning
...